Evaluation of efficacy of levetiracetam on cognitive symptoms in schizophrenic patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101130005280N32

Enrollment

Registered

2020-04-06

Start date

2019-10-23

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenic. Schizophrenia

Interventions

Intervention 1: Intervention group: levetiracetam (LEV) group, after 2 weeks of antipsychotic treatment, 2-week baseline period at 250 mg LEV dose and increase to maximum LEV dose (500 mg twice daily

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 6-month to 10-year history of schizophrenia Have a normal IQ Do not be in the acute phase of schizophrenia. The patient do not take anticholinergic and benzodiazepine medications do not history of drug use in the past 6 months (except nicotine) Do not be pregnant or breastfeeding (Pregnancy Detection Based on BHCG Pregnancy Test)

Exclusion criteria

Exclusion criteria: Lack of consent for participation in the study Serious medical illness

Design outcomes

Primary

Measure	Time frame
Cognitive function. Timepoint: At baseline, weeks 4 and 8. Method of measurement: Wisconsin questionnaire, Stroop test.;Quality of Life. Timepoint: At baseline, weeks 4 and 8. Method of measurement: The Positive and Negative syndrome Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Behdani

Mashhad University of Medical Sciences

behdanif@mums.ac.ir+98 51 3711 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026